• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan+
  • Classics™+
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Oncology

Effectiveness of lorlatinib in advanced anaplastic lymphoma kinase-positive lung cancer

bySze Wah Samuel ChanandDeepti Shroff Karhade
November 24, 2020
in Oncology, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. In this randomized, double-blind, phase three trial, progression-free survival was higher in patients treated with lorlatinib compared with crizotinib.

2. Lorlatinib treated patients had improved overall cancer response including greater intracranial response.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Anaplastic lymphoma kinase (ALK) chromosome rearrangement is a target for anti-cancer treatment in advanced non-small cell lung cancer (NSCLC). Crizotinib was one of the first agents targeting ALK-positive tumors. Lorlatinib is a 3rd generation ALK targeting agent with previous data suggesting improved blood-brain barrier penetration and improved durability against drug-resistant mechanisms. This was a randomized, double-blind, placebo-controlled trial of untreated advanced ALK-positive NSCLC patients comparing lorlatinib vs. crizotinib and this article detailed the results of the interim analysis. Progression-free survival (PFS) and the objective response rate (ORR) favored the lorlatinib group compared to crizotinib. Of those with CNS metastases, lorlatinib induced a higher intracranial response and the time to CNS progression was longer. Hypercholesteremia, hypertriglyceridemia, hypertension, and weight gain were noted to be higher in the lorlatinib group while diarrhea, nausea, and vomiting were higher in the crizotinib group. There should be caution for the interpretation of this paper as overall survival data had not matured enough to detect a difference. As well, 2nd generation ALK inhibitors have been demonstrated to be superior to crizotinib which makes it unclear what is the more optimal 1st line therapy. Overall, this interim analysis of a phase 3 trial comparing lorlatinib and crizotinib showed promising results, specifically the improvement in CNS metastases; however, more data will be needed to determine which is more appropriate therapy to replace crizotinib as 1st line therapy for untreated ALK-positive NSCLC.

Click here to read the study in the NEJM

Relevant Reading: ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer

RELATED REPORTS

#VisualAbstract: Tarlatamab Improves Survival in Small-Cell Lung Cancer after Platinum-Based Chemotherapy

Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy

#VisualAbstract: Tarlatamab Improves Survival in Small-Cell Lung Cancer after Platinum-Based Chemotherapy

In-Depth [randomized controlled trial]: This was a phase three, double-blind, placebo-controlled, randomized trial of 296 persons with untreated advanced ALK-positive NSCLC. The primary endpoint for this interim analysis was PFS and analyzed in the intention-to-treat population. PFS was longer in the lorlatinib group compared with crizotinib (hazard ratio (HR) 0.21; 95% confidence interval (CI), 0.14 to 0.31). At the 12-month mark, 78% were alive in the lorlatinib group and 39% in the crizotinib group. ORR was 76% in lorlatinib treated patients compared to 27% in crizotinib treated patients. Among those with brain metastases at baseline, an intracranial response was found in 66% (95% CI, 49 to 80%) of the lorlatinib group compared to 20% (95% CI, 9 to 36%) in the crizotinib group. Patients without CNS progression at the time of analysis were 96% (95% CI, 91 to 98%) in the lorlatinib group and 60% (95% CI, 49 to 69%) in the crizotinib group (HR, 0.07; 95% CI, 0.03 to 0.17). The most common grade 3-4 adverse events in the lorlatinib group were hypertriglyceridemia (20%), weight gain (17%) and hypercholesteremia (16%) and hypertension (10%). Adverse events leading to treatment discontinuation occurred in 7% of the lorlatinib group and 9% for the crizotinib group.

Image: PD

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: Anaplastic lymphoma kinase (ALK)Crizotiniblorlatiniblung cancer
Previous Post

#VisualAbstract: U.S. National trend of COVID-19 cases in children

Next Post

#VisualAbstract: Post-extubation high-flow nasal cannula associated with higher rates of treatment failure in preterm infants

RelatedReports

#VisualAbstract: Tarlatamab Improves Survival in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
StudyGraphics

#VisualAbstract: Tarlatamab Improves Survival in Small-Cell Lung Cancer after Platinum-Based Chemotherapy

July 4, 2025
Patient Basics: Lung Cancer Overview
Chronic Disease

Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy

July 2, 2025
#VisualAbstract: Tarlatamab Improves Survival in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
StudyGraphics

#VisualAbstract: Tarlatamab Improves Survival in Small-Cell Lung Cancer after Platinum-Based Chemotherapy

June 19, 2025
Lessons from real-world implementation of lung cancer screening
AI Roundup

Sacituzumab tirumotecan may have a role in the treatment of metastatic non-small cell lung cancer

June 10, 2025
Next Post
#VisualAbstract: Plant-based QVLP influenza vaccine likely non-inferior to commercial inactivated vaccines

#VisualAbstract: Post-extubation high-flow nasal cannula associated with higher rates of treatment failure in preterm infants

Insulin costs rose exponentially, regardless of formulation or patent

Golimumab effective at preserving insulin production in type 1 diabetes

#VisualAbstract: Plant-based QVLP influenza vaccine likely non-inferior to commercial inactivated vaccines

#VisualAbstract: Plant-based QVLP influenza vaccine likely non-inferior to commercial inactivated vaccines

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Seventh cervical nerve neurotomy may augment speech therapy in patients with chronic aphasia post-stroke
  • Time-restricted eating does not confer changes in sleep, mood, or quality of life
  • Commonly cited medication triggers may not increase risk of microscopic colitis among older adults
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • AI Roundup
  • Pharma
  • The Scan
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Podcasts
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account
No Result
View All Result

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.